Connection

RADEK SKODA to Janus Kinase 2

This is a "connection" page, showing publications RADEK SKODA has written about Janus Kinase 2.
Connection Strength

13.857
  1. Loss of Socs2 improves molecular responses to IFNa in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F. Leukemia. 2025 Apr; 39(4):876-887.
    View in: PubMed
    Score: 0.865
  2. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-a in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024 06 13; 143(24):2490-2503.
    View in: PubMed
    Score: 0.822
  3. The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Adv. 2024 05 14; 8(9):2312-2325.
    View in: PubMed
    Score: 0.817
  4. Inhibition of interleukin-1? reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nat Commun. 2022 09 13; 13(1):5346.
    View in: PubMed
    Score: 0.728
  5. JAK2-V617F and interferon-a induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood. 2021 04 22; 137(16):2139-2151.
    View in: PubMed
    Score: 0.661
  6. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood. 2020 11 26; 136(22):2591-2595.
    View in: PubMed
    Score: 0.643
  7. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019 11 21; 134(21):1832-1846.
    View in: PubMed
    Score: 0.599
  8. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016 07 25; 213(8):1479-96.
    View in: PubMed
    Score: 0.474
  9. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016 08 11; 128(6):839-51.
    View in: PubMed
    Score: 0.472
  10. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 2015 Mar 26; 125(13):2131-40.
    View in: PubMed
    Score: 0.428
  11. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014 Oct 20; 211(11):2213-30.
    View in: PubMed
    Score: 0.420
  12. Less Jak2 makes more platelets. Blood. 2014 Oct 02; 124(14):2168-9.
    View in: PubMed
    Score: 0.420
  13. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood. 2014 Jun 19; 123(25):3943-50.
    View in: PubMed
    Score: 0.408
  14. Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica. 2014 Apr; 99(4):e52-4.
    View in: PubMed
    Score: 0.401
  15. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013 Feb 14; 121(7):1188-99.
    View in: PubMed
    Score: 0.371
  16. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010 Mar 11; 115(10):2003-7.
    View in: PubMed
    Score: 0.302
  17. Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009; 159-67.
    View in: PubMed
    Score: 0.282
  18. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009 Feb 26; 113(9):2022-7.
    View in: PubMed
    Score: 0.280
  19. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008 Dec; 93(12):1890-3.
    View in: PubMed
    Score: 0.276
  20. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood. 2008 Apr 01; 111(7):3863-6.
    View in: PubMed
    Score: 0.263
  21. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008 Jan; 93(1):34-40.
    View in: PubMed
    Score: 0.263
  22. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008 Apr 15; 111(8):3931-40.
    View in: PubMed
    Score: 0.262
  23. Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders. Eur J Haematol Suppl. 2007 Oct; (68):5-8.
    View in: PubMed
    Score: 0.258
  24. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007 Jul 01; 110(1):375-9.
    View in: PubMed
    Score: 0.249
  25. Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity. J Med Chem. 2024 Jun 27; 67(12):10012-10024.
    View in: PubMed
    Score: 0.205
  26. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023 04 27; 141(17):2127-2140.
    View in: PubMed
    Score: 0.190
  27. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023 04 20; 141(16):1909-1921.
    View in: PubMed
    Score: 0.190
  28. Myeloproliferative Neoplasms: The Long Wait for JAK2-Mutant Clone Expansion. Cell Stem Cell. 2021 03 04; 28(3):359-361.
    View in: PubMed
    Score: 0.164
  29. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019 03 04; 129(4):1596-1611.
    View in: PubMed
    Score: 0.142
  30. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica. 2019 04; 104(4):710-716.
    View in: PubMed
    Score: 0.139
  31. HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nat Commun. 2018 04 12; 9(1):1431.
    View in: PubMed
    Score: 0.134
  32. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A. 2015 Apr 14; 112(15):4642-7.
    View in: PubMed
    Score: 0.109
  33. Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell. 2014 Dec 04; 15(6):791-804.
    View in: PubMed
    Score: 0.106
  34. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 03; 123(14):2220-8.
    View in: PubMed
    Score: 0.100
  35. Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia. Blood. 2013 Nov 21; 122(22):3694-6.
    View in: PubMed
    Score: 0.099
  36. JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report. Acta Haematol. 2013; 129(1):23-5.
    View in: PubMed
    Score: 0.091
  37. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol. 2011 Aug 14; 18(9):971-6.
    View in: PubMed
    Score: 0.084
  38. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood. 2011 Feb 10; 117(6):2075-6.
    View in: PubMed
    Score: 0.081
  39. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011 Mar 10; 117(10):2813-6.
    View in: PubMed
    Score: 0.081
  40. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia. 2009 Oct; 23(10):1708-15.
    View in: PubMed
    Score: 0.073
  41. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol. 2009 Jul; 146(2):150-7.
    View in: PubMed
    Score: 0.072
  42. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia. 2009 Oct; 23(10):1924-6.
    View in: PubMed
    Score: 0.072
  43. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica. 2009 Jan; 94(1):38-45.
    View in: PubMed
    Score: 0.070
  44. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? Leukemia. 2008 Jul; 22(7):1459-63.
    View in: PubMed
    Score: 0.066
  45. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008 Feb 01; 111(3):1686-9.
    View in: PubMed
    Score: 0.065
  46. Advances in the understanding and management of myeloproliferative disorders. Eur J Haematol Suppl. 2007 Oct; (68):2-4.
    View in: PubMed
    Score: 0.065
  47. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006 Aug 15; 108(4):1377-80.
    View in: PubMed
    Score: 0.059
  48. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005 Nov 15; 106(10):3374-6.
    View in: PubMed
    Score: 0.056
  49. Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005 Jul; 90(7):871-4.
    View in: PubMed
    Score: 0.055
  50. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28; 352(17):1779-90.
    View in: PubMed
    Score: 0.055
  51. Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis. Nat Commun. 2023 10 12; 14(1):6414.
    View in: PubMed
    Score: 0.049
  52. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017 12 28; 130(26):2848-2859.
    View in: PubMed
    Score: 0.032
  53. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol. 1997 Apr; 11(4):393-9.
    View in: PubMed
    Score: 0.031
  54. Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms. Mol Carcinog. 2017 02; 56(2):567-579.
    View in: PubMed
    Score: 0.030
  55. Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. 2014 Dec; 12(12):2120-30.
    View in: PubMed
    Score: 0.026
  56. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 07; 512(7512):78-81.
    View in: PubMed
    Score: 0.026
  57. Dkk3 levels in patients with myeloproliferative neoplasms. Thromb Res. 2014 Feb; 133(2):218-21.
    View in: PubMed
    Score: 0.025
  58. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009 Nov; 6(11):627-37.
    View in: PubMed
    Score: 0.019
  59. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia. 2008 Nov; 22(11):1975-89.
    View in: PubMed
    Score: 0.017
  60. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006 Sep 15; 108(6):1865-7.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.